Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc. is a U.S.-based commercial-stage biopharmaceutical company focused on therapies for chronic endocrine and neurological diseases. Its business combines marketed prescription products, specialty-pharmacy distribution, and a proprietary formulation platform used to develop injectable medicines.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaApproved products for endocrine disorders and related rare diseases.
Gvoke products used to treat severe hypoglycemia.
Keveyis for Primary Periodic Paralysis.
XP-8121 development and formulation collaborations using XeriSol/XeriJect.
Tuotteet
Raportoitu · osuus liikevaihdosta- Recorlev47,7 %
- Gvoke32,2 %
- Keveyis16,3 %
- Royalty Contract and Other Revenue3,0 %
- Product Other0,7 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Xeris sells primarily to pharmaceutical wholesalers and specialty pharmacies, which then distribute products to patients and retail pharmacies. Its end users are patients with rare or chronic endocrine and neurological conditions, while payors and healthcare providers influence access, reimbursement, and utilization. The company also works with pharmaceutical partners on formulation development for proprietary drugs and biologics.
Buy finished Recorlev, Gvoke, and Keveyis for broad downstream distribution.
Dispense the company’s products to patients and manage specialty access workflows.
Use Recorlev for Cushing’s syndrome and related hypercortisolemia treatment.
Use Gvoke rescue products for emergency glucagon administration.
Use Keveyis to treat PPP and related variants.
Engage Xeris for formulation development using XeriSol and XeriJect.
Strategia
Xeris’ strategy is to expand the commercial reach of Recorlev, Gvoke, and Keveyis while advancing XP-8121 through late-stage development. It also seeks to monetize its non-aqueous formulation platforms through partnerships, using commercial product cash generation to support pipeline investment.
The company’s current revenue base depends on Recorlev, Gvoke, and Keveyis.
A late-stage levothyroxine product could broaden the endocrine franchise.
Partnerships can create non-product revenue and validate XeriSol/XeriJect.
Third-party manufacturing and distribution keep capital intensity lower.
Maantiede
Xeris generates revenue primarily in the United States and markets its approved products there. Its supply chain is also geographically distributed, with manufacturing and assembly across the U.S., Switzerland, and Taiwan through third-party contractors. That structure concentrates commercial exposure in the U.S. while creating operational dependence on cross-border suppliers and contract manufacturers.
Riskit
Xeris depends on a small number of customers, third-party manufacturers, and a limited set of commercial products, so execution or supply disruptions can quickly affect results. It also faces typical biopharma risks around regulatory approval, clinical development, reimbursement, patent protection, and the need for additional financing.
- Customer concentrationVaikutus: KorkeaTodennäköisyys: Kohtalainen
A small number of customers account for most product revenue and receivables.
Kohdistuu: Four customers over 90% of gross product revenue
- Single-source and third-party supply dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
Key APIs and drug products are sourced from external manufacturers.
Kohdistuu - Regulatory and clinical development riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
XP-8121 and other pipeline efforts require FDA review and successful trials.
Kohdistuu: Phase 3 planning and approval pathway
- Financing riskVaikutus: KeskitasoTodennäköisyys: Korkea
The company may need additional capital to fund commercialization and R&D.
Kohdistuu: Public or private debt/equity financing
- Reimbursement and pricing pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Net revenue depends on rebates, chargebacks, discounts, and payer access.
Kohdistuu: Specialty pharmacy and wholesaler channel
- Intellectual property riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Value depends on protecting proprietary formulation science and product rights.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätRebates, chargebacks, discounts, copay assistance, and returns reduce reported product revenue.
Vaikutus: Can materially change net sales versus gross shipments
Product revenue is recognized when control transfers to wholesalers or specialty pharmacies.
Vaikutus: Quarterly revenue can shift with channel inventory and ordering patterns
Outsourced manufacturing creates exposure to excess, slow-moving, or committed inventory.
Vaikutus: Can affect cost of goods sold and reserve estimates
Partnership income is recognized under contract terms when earned and estimable.
Vaikutus: Adds variability outside core product sales
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
BioVie Inc
BIVIW · Pharmaceutical Preparations
Corcept Therapeutics Incorporated
CORT · Pharmaceutical Preparations
Corcept Therapeutics is a U.S.-based commercial-stage pharmaceutical company focused on medicines that modulate cortisol, with its core marketed product Korlym…
Immix Biopharma, Inc.
IMMX · Pharmaceutical Preparations
Kairos Pharma, LTD.
KAPA · Pharmaceutical Preparations
Amylyx Pharmaceuticals, Inc.
AMLX · Pharmaceutical Preparations
X4 Pharmaceuticals, Inc
XFOR · Biological Products, (No Diagnostic Substances)
Päivitetty: 24.9.2026